More News

Could anaemia drug have potential as cancer treatment?

Jim Cornall -
Common medications used to treat anaemia may also slow down cancer cell growth, according to new research from Finland. Researchers...

Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges

Jim Cornall -
This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO...

Paediatric pneumococcal vaccine programme advancing

Jim Cornall -
Pfizer Inc. has announced data from its phase 2 study evaluating the safety, tolerability and immunogenicity of a four-dose...

FDA clearance for universal dual-target CAR-T candidate

Jim Cornall -
Qihan Biotech’s QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). QT-019C is...

Positive data from chronic scrotal content pain trial

Jim Cornall -
Sustained Therapeutics, Inc. has presented additional data from its phase 2 study evaluating ST-01, a proprietary non-opioid sustained-release small...

Thalassaemia treatment gets EU approval

Jim Cornall -
Agios Pharmaceuticals, Inc. has revealed that the European Commission has granted marketing authorisation for PYRUKYND (mitapivat), an oral pyruvate...

New data from Parkinson’s disease trial

Jim Cornall -
TreeFrog Therapeutics is presenting new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue...

Restoring the “longevity protein”

Jim Cornall -
Avaí Bio, Inc., an emerging biotechnology company developing cell-based therapies for diabetes, age-related disorders, and anti-aging, has announced -...

Positive topline results from phase 2 recurrent ovarian cancer trial

Jim Cornall -
OSE Immunotherapeutics SA has announced the release of the abstract selected for an oral presentation at the upcoming ASCO...

Rare oral cancer has distinct genetic profile

Jim Cornall -
Cancer diagnosis can be challenging, and delayed diagnosis can allow cancer to progress, complicating treatment. Oral squamous cell carcinoma (OSCC),...

New tool decodes structures and motifs of RNA

Jim Cornall -
Modern biology now looks deeper into the cells of living organisms than ever before. Researchers from the chairs of...

Elite immune cells lead fight against multiple myeloma

Jim Cornall -
Immunotherapy for cancer works like a guided missile, directing the body’s immune cells toward tumour cells. However, not all...

National framework to strengthen UK advanced therapy clinical trials

Jim Cornall -
A new framework designed to support the standardisation and expansion of advanced therapy clinical trials has launched in the...

Sensor detects Alzheimer’s and Parkinson’s in blood

Jim Cornall -
For the first time, therapeutically effective medications are now available for Alzheimer’s disease. Effective symptomatic therapies also exist for...

Base to Base biotech podcast 60: Delivery method reduces prostate cancer tumour size

Jim Cornall -
This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster. Base...

Pilot trial suggests anti-inflammatory drug could help difficult-to-treat depression

Jim Cornall -
Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from...

Global collaboration on Kawasaki disease key to reducing risk of serious heart conditions

Jim Cornall -
International collaboration in research, diagnosis and care is critical to reducing the risk of serious heart conditions for children...

Phase 1b data from post-immunotherapy hepatocellular carcinoma in liver cancer shared

Jim Cornall -
Agenus Inc. has announced the publication of phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination...

Promising results from LGMD-R5 limb-girdle muscular dystrophy gene therapy trial

Jim Cornall -
Atamyo Therapeutics, which specialises in the development of gene therapies for limb-girdle muscular dystrophy (LGMD), has announced the first...

ADDF praises Alzheimer’s drug progress

Jim Cornall -
Biogen has announced topline results from its phase 2 CELIA study of diranersen, an investigational therapy designed to target...

Challenging assumptions about lymph node radiation therapy in breast cancer

Jim Cornall -
Final results from an EORTC randomised trial with more than 20 years of follow-up show that irradiation of the...